公开(公告)号：US11098072B2

公开(公告)日：2021-08-24

申请号：US16627004

申请日：2018-06-27

申请人： The George Washington University ,  Washington University in St. Louis ,  George Mason University ,  Saint Louis University

发明人： Cynthia Dowd ,  Xu Wang ,  Robert Carl Brothers ,  Audrey Ragan Odom John ,  Rachel Edwards ,  Marvin Meyers ,  Stacy Arnett ,  Robin Couch ,  Kenneth Heidel

IPC分类号： C07F9/38 ,  A61P33/06 ,  A61P31/06 ,  C07F9/40

摘要： The present disclosure relates to novel compounds, pharmaceutical compositions, and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum or related Plasmodium parasite species and Mycobacterium tuberculosis or related Mycobacterium bacteria species. The compounds are α,β-unsaturated analogs of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum.

公开(公告)号：US11191754B2

公开(公告)日：2021-12-07

申请号：US16533204

申请日：2019-08-06

申请人： Saint Louis University

发明人： John Edwin Tavis ,  Lynda Anne Morrison ,  Marvin Meyers

IPC分类号： A61K31/4412 ,  C07D213/89 ,  A61P31/12 ,  C12N9/22 ,  A61P31/22 ,  A61K9/00 ,  A61K31/122 ,  A61K31/4375 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K31/662 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7076 ,  A61K38/21 ,  C07C50/28 ,  C07D471/04

摘要： The present disclosure relates to identification of inhibitors of hepatitis and herpesvirus replication including compounds of the formula: wherein the variables are as defined herein. Also provided are methods of treatment using agents so identified.

公开(公告)号：US20190328706A1

公开(公告)日：2019-10-31

申请号：US16401950

申请日：2019-05-02

申请人： Saint Louis University ,  Washington University

发明人： Peter Ruminski ,  Marvin Meyers ,  Richard F. Heier ,  Michael Rettig ,  John DiPersio ,  Darja Karpova

IPC分类号： A61K31/397 ,  A61K31/135 ,  C07D207/48 ,  C07D205/04 ,  C07C233/87 ,  A61K31/197 ,  A61K31/40

摘要： The present disclosure provides therapeutic agents including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such therapeutic agents. Methods of using the therapeutic agents are also provided. The present disclosure further provides combinations of a VLA-4 inhibitor and an agent which interacts with a chemokine receptor, and methods of use thereof. In some embodiments, the disclosed combinations may be used in a method of mobilizing hematopoietic stem cells. In some embodiments, the disclosed methods may be used in the treatment of a condition which requires the collection of hematopoietic stem cells for transfusions or in chemotherapy. The present disclosure further provides methods of treating a patient comprising administering an agent which interacts with a chemokine such as G-CSF, plerixafor, or Gro-β and VLA-4 inhibitors.